ABSTRACT In the past few years, silk fibroin (SF) has commanded substantial attention from both academic researchers and industrial developers owing to its inherent biocompatibility, biodegradability, hydrophilicity, and presence of biologically active domains that promote cell adhesion and proliferation. Despite the aforementioned advantages, limitations pertaining to the mechanical strength and processing constraints of pristine SF restrict its broad biomedical applicability. Accordingly, efforts have been directed to overcome these limitations by employing electrospun silk fibroin/poly (lactic acid) (SF/PLA) nanofibrous systems as a class of hybrid biomaterials where the biocompatibility of SF is strategically integrated with the mechanical stability, structural integrity, and predictable degradation behavior of PLA. Electrospinning allows the fabrication of porous, extracellular matrix‐mimetic scaffolds with tailorable physicochemical properties, including fiber diameter, porosity, surface chemistry, and mechanical behavior. Over the past decade, SF/PLA electrospun scaffolds have been extensively explored for broad‐spectrum applications, including implantable medical devices, tissue engineering, and wound healing, due to their adaptability and favorable cell‐material interactions. However, a comprehensive overview of the silk origin, electrospinning parameters, structure–property relationships, and biological response profile of these systems remains limited. In this review, we systematically collated emerging advances in SF/PLA electrospun fibrous scaffolds, emphasizing the influence of blend composition and operational parameters on fiber diameter (~100–800 nm), porosity, surface wettability (water contact angle ~54°–135°), mechanical properties, and degradation behavior. Finally, the translational potential of SF/PLA electrospun scaffolds is critically discussed across multifaceted applications, including dermal, bone, cartilage, vascular, cardiac, hernia, and ocular tissue regeneration, positioning these systems as next‐generation platforms for regenerative medicine.
Manisha et al. (2026) studied this question.